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Paul Szabo4 and Marc E Weksler1*
Abstract
Background: The incidence and growth of cancer has been reported to increase with age and/or impaired T
lymphocyte function.
Results: Consistent with these observations, we found that a monoclonal serum immunoglobulin (mIgG2b), rarely
detectable after the injection of 5T33 murine multiple myeloma (MMM) cells into 3–4 month old wild-type C57BL/6
mice was seen more frequently in 18–20 month old wild-type C57BL/6 mice and in 3–4 month old Rag1-deficient
C57BL/6 mice. These observations were confirmed and extended using more sensitive assays such as quantitation
of splenic mRNA specific for the canonical 5T33 monoclonal IgG2b produced by 5T33 myeloma cells and the most
sensitive assay, photon-imaging of mice injected with 5T33 cells, stably transfected with fire-fly luciferase gene
(5T33L cells), which emit photons after the injection of luciferin. Furthermore, the proliferation of 5T33L myeloma
cells in Rag1-deficient C57BL/6 mice was greater in mice which also received spleen T cells from 18–20 month old
C57BL/6 wild-type mice compared to mice which received splenic T cells from 3–4 month old C57BL/6 wild-type
mice. Thus, immune reconstitution of C57BL/6 mice with splenic T cells from young wild-type mice offered greater
protection from progressive growth of 5T33L myeloma cells than did reconstitution with splenic T cells from old
mice.
Conclusions: Our findings support the hypothesis that age-associated changes in splenic T cell function contribute
to the increased growth of 5T33 MMM cells in old compared to young C57BL/6 mice. Should similar processes
occur in humans, increasing the anti-myeloma activity of T cells in old patients with multiple myeloma or
transferring cryopreserved, young, autologous, T cells might benefit elderly patients with multiple myeloma.
Background
The frequency of human cancer, in general, and in mul-
tiple myeloma, in particular, increases exponentially with
age through the eighth decade of life [1,2]. A similar
phenomenon has also been observed in experimental
animals. Thus, pristane induces more plasmacytomas in
old than in young mice [3]. Furthermore, the exponential
increase in cancer with age implies that two or more age-
associated factors contribute to the increased rate of devel-
opment of neoplasms late in life. One age-associated factor
in carcinogenesis is the accrual of genetic aberrations
associated with the sequential transition of normal tissues
to benign neoplasms and then to malignant neoplasms [4].
The link between a sequential appearance of genetic
aberrations and neoplastic transformation has been exten-
sively studied in human colon cancer where over decades
the accrual of genetic aberrations in colonic epithelial
cells leads to the transition from early to late adenomas
and then to carcinomas [5]. A second factor, immune sen-
escence, associated with impaired T cell function, has
been reported to compromise immune surveillance and
favor the growth and dissemination of neoplasms with in-
creasing age [6]. Increasing experimental support suggests
that tumors arise and progress more frequently in
immunologically-compromised hosts although direct evi-
dence that the age-associated decline in immune surveil-
lance contributes to the exponential increase in tumor
growth late in life has been difficult to demonstrate [7-9].
We have studied the growth of 5T33 MMM cells in
C57BL/6 mice because myeloma in mice as in humans
is a highly age-dependent cancer [10]. The 5T33 MMM
* Correspondence: weksler@med.cornell.edu
1Department of Medicine, Weill Cornell Medical College, New York, NY, USA
Full list of author information is available at the end of the article
IMMUNITY & AGEING
© 2013 Glick et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Glick et al. Immunity & Ageing 2013, 10:5
http://www.immunityageing.com/content/10/1/5
cell line was derived from a spontaneous tumor that arose
in an old, C57BL/KalwRij mouse and subsequently was
adapted to grow in tissue culture [11]. We and others
have studied the growth of 5T33 MMM cells in C57BL/6
mice because a number of mutant lines of this mouse
strain are available from the Jackson Laboratories (Bar
Harbor, Maine) and because old and young C57BL/6 mice
are available from a colony maintained by the National
Institute on Aging [12]. We now report that the age-
associated increase in the growth of 5T33 MMM cells in
old C57BL/6 mice reflects impaired immune surveillance
associated with senescence of T lymphocytes.
Results
Growth of 5T33 MMM cells in C57BL/6 mice is influenced
by age and T lymphocyte immune senescence
The growth of 5T33 MMM cells in C57BL/6 female mice
is reflected in the level of the specific monoclonal IgG2B
produced by the 5T33 MMM cells that can be detected
by serum protein electrophoresis (SPEP). We injected
5T33 MMM cells intravenously into four groups of fe-
male C57BL/6 mice: (1) wild type C57BL/6 3–4 month
old; (2) wild type18–20 month old C57BL/6 mice; (3)
3–4 month old T- and B-cell deficient C57BL/6 mice, and
(4) B-cell deficient (IgH-/IgH-) C57BL/6 mice. The rate
and frequency of development of the mIgG2B serum
monoclonal band, detected by SPEP, differed among the
four groups (Figure 1).
The group of mice that developed the mIg band most
rapidly and at the highest frequency was made up of
young Rag1-deficient mice. This group also developed
the highest percentage of mice with the mIg band (93%
of 28 mice). The group that was next most rapid to de-
velop the mIg band was the 18–20 month old wild type
C57BL/6 mice. This group also had the second highest
percentage of affected mice (35%). The groups least sus-
ceptible to developing the mIg band were young wild
type C57BL/6 mice (6%) and the B-cell deficient young
C57BL/6 mice (10%). The differences between the two
fastest and two slowest groups to develop the mIg band
were significant (Kaplan-Meier statistic p < 0.021). To-
gether, these studies suggest that aging and the conse-
quent senescence of T cells, or T cell deficiency at any
age, increases susceptibility to the growth of the 5T33
myeloma.
Another potential factor influencing the appearance of
the 5T33 mIg is the innate susceptibility of old mice to
develop spontaneously mIgs. As we previously reported,
approximately 50% of 18–20 month old wild-type
C57BL/6 mice spontaneously developed age-associated
serum mIg that differed in mobility and isotype from the
mIg produced by 5T33 MMM cells [13,14]. It was not
known whether 18–20 month old C57BL/6 mice with
age-associated mIg were more susceptible to progressive
5T33 MMM cell growth following injection into old
C57BL/6 mice and we found no significant difference in
the frequency of 5T33 MMM cell-specific mIg in 18–20 -
month old C57BL/6 mice with (6/15) or without (6/19)
spontaneous, age-associated mIg.
IgH CDR3 analysis detects 5T33 cells in the spleen of sick
mice without 5T33-specific mIg in their serum
A small number of Rag1-deficient and old wild type
C57BL/6 mice appeared ill 2 to 3 months after injection
of 5T33 cells but did not have detectable serum 5T33
mIg. It was possible that 5T33 MMM cells were present
albeit not in sufficient numbers to produce a detectable
serum 5T33-specific mIg although they caused morbid-
ity in the mice. We used IgH CDR3 mRNA sequence
and length analysis to identify 5T33 MMM cells within
the spleen producing 5T33 MMM mRNA. This more
sensitive technique we had used in detecting the spleen
cells from 18 month old mice producing age-associated
mIg.
Two of 28 young C57BL/6 Rag1-deficient mice injected
with 5T33 MMM cells did not express a 5T33-specific
serum mIg (Figure 1). These mice, despite showing weight
loss and other signs of tumor morbidity, did not have a
detectable IgG2b band on SPEP. However, when these
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Figure 1 Growth of 5T33-MMM cells was measured by the
presence of 5T33-specific IgG2b mIg in serum. Ten million
HBSS-washed cultured 5T33 MMM cells were injected into 4 groups
of mice on day 0: Group 1 included 18 young (2-3-month old), wild-
type, C57BL/6 mice; Group 2 included 10 young (2–3 month-old)
B-cell-deficient IgH−/− (B6.129S2-Igh-6tm1Cgn/J) C57BL/6 mice; Group
3 included 34 aged (18–20 month old) wild-type C57BL/6 mice; and
Group 4 included 28 young (2-3-month-old) Rag1-deficient C57BL/6
B-cell and T-cell deficient mice (B6.127S7-Rag1tm1Mom/J). The
difference in percentages between mice with mIg in young RAG-1
deficient and old wild-type C57BL/6 mice and between old wild-
type C57BL/6 and B-cell deficient or young wild-type C57BL/6 mice
were statistically different (Kaplan-Meier statistic, p < 0.021).
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animals were sacrificed, IgG2b CDR3 mRNA analysis
revealed that both of these mice expressed the canonical
CDR3 length and sequence of the rearranged 5T33 IgG2b
genes in their spleens. Thus, 100% of Rag1-deficient mice
supported the growth of 5T33 cells using this more sensi-
tive technique although 2 of the 28 mice did not have de-
tectable serum 5T33 mIg.
In a second experiment 8 of 17 18–20 month old wild
type C57BL/6 mice did not develop 5T33-specific serum
mIg. Two of these 8 mice expressed 5T33-specific IgG2b
CDR3 RNA in the spleen. Thus, 11 of 17 (nearly 65%) of
this group of 18–20 month old C57BL/6 mice supported
the growth of 5T33 MMM cells when measured by IgG2b
CDR3 mRNA analysis. Importantly, analysis showed that
IgG2b CDR3 mRNA analysis detected a greater susceptibil-
ity of Rag-1 deficient 3–4 month old C57BL/6 mice (100%
5T33 MMM cells positive) compared to 18–20 month old
C57BL/6 wild type mice (65% 5T33 MMM cells positive).
IgH CDR3 analysis can be used to detect 5T33 cells in the
spleen before serum mIgG is detectable
Fewer than 50% of Rag1-deficient mice injected with 10
million 5T33 MMM cells had detectable serum 5T33
mIg within 4 weeks of the injection of 5T33 MMM cells
(Figure 1). However, when IgH CDR3 mRNA length and
sequence analysis were used to identify 5T33 MMM
cells in the spleens, most mice had detectable splenic
5T33 MMM cells before they had developed the 5T33-
specific serum mIg. When young and old mice were
injected with 10 million 5T33 myeloma cells and a par-
tial splenectomy was performed one or two days later,
all mice had 5T33 MMM cells in the spleen. However,
the number of 5T33 MMM cells had significantly
decreased within 21 days after injection into young but
not in old mice based on 5T33 IgH CDR3 mRNA ana-
lysis (Figure 2A). The survival index of 5T33 MMM cells
is represented by the area of an individual splenic 5T33-
specific IgH CDR3 mRNA peak. In 10 young mice the
average survival index progressively declined following
5T33 MMM cell injection. In contrast, in old mice the
average survival index did not change significantly be-
tween the 2nd and the 21st day following the injection of
5T33 MMM cells. Consequently, 21 days following the
injection of 5T33 MMM cells, the average 5T33 cell
IgG2b survival index was significantly higher in old than
in young C57BL/6 wild-type mice (Wilcoxin-Mann–
Whitney rank sum test p < 0.036).
Development of a 5T33 line constitutively expressing the
firefly luciferase gene
As guidelines for animal experimentation limit the
number and frequency of survival surgeries, it was not
possible to monitor the mass of 5T33L MMM cells
after injection by repeated partial splenectomies. To
A
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Young wild type
Old wild type
Figure 2 A. The number of 5T33 MMM cells in the spleen was
estimated by the area of the IgH CDR3 mRNA peak with the
length and sequence analysis of cDNA of 5T33 MMM cells
using ImageJ Version 1.37 (NIH, Bethesda, MD). Splenic samples
were obtained by partial splenectomy, 1, 2, or, at sacrifice, 21 days
after injection after injection of 5T33 MMM cells. Splenic 5T33 cell
number in young wild type C57BL/6 mice decreased by nearly 50%
between day 1 and 2 and by 70% between day 2 and 21 following
the injection of 5T33 MMM cells. In contrast, in old mice decreased
only 30% and less than 5% between day 1 and 2 and less than 5%
between day 2 and 21. After 21 days the index of 5T33 MMM cells
remaining in the spleen was 4 fold greater in old than in young
mice (p=0.036, Mann-Whitney Rank Sum Test). B. The average
growth of 10 million luciferase-transfected 5T33 MMM (5T33L) cells
injected into 3 young wild-type C57BL/6 mice or into 5 C57BL/6
Rag1-deficient mice by the average photon flux during the 7 weeks
following the injection of 10 million 5T33L MMM cells. The average
photon flux was measured using an IVIS optical imaging system
after 20 minutes, 2 days, and at weekly intervals following 5T33L
MMM cell infection for 7 weeks. Within 14 days the difference in the
average photon flux of the C57BL/6-Rag-1-deficient and C57BL/6
wildtype mice was significantly different (p < 0.036 Wilcoxin-Mann-
Whitney rank sum test) and increased progressively thereafter.
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overcome this limitation, we created a line of 5T33
MMM cells stably transfected with the firefly luciferase
gene that we termed 5T33L MMM cells that constitu-
tively expressed the firefly luciferase gene. After the in-
jection of 5T33L MMM cells, it was possible to
repeatedly measure 5T33L MMM cell load in the same
mice over long periods of time (Figure 2B). Two days
after the injection of 10 million 5T33L MMM cells, pho-
ton flux following the injection of luciferin was the same
in both young and Rag1-deficient C57BL/6 mice,
confirming the findings using IgH CDR3 mRNA length
analysis. However, by 5 days after injection of the 5T33L
MMM cells and thereafter the load of 5T33L MMM
cells began to diverge in young, wild type as compared
to young, Rag1-deficient C57BL/6 when measured by
total photon flux. Fourteen days after the injection of
5T33L into young, wild type C57BL/6 mice the photon
flux has fallen to background levels comparable to pho-
ton flux from mice that had not received any 5T33L
cells. There was no change in the background photon
flux in young wildtype C57BL6 mice during the subse-
quent 6 weeks of observation. This is consistent with
observations using 5T33-specific CDR3-mRNA peak
area observed during the first 3 weeks following the in-
jection of 5T33L MMM cells (Figure 2A). In contrast,
the photon flux from 5T33L MMM cells increased expo-
nentially between 14 and 50 days after 5T33L MMM cell
injection into Rag1-deficient mice (Figure 2B). As early
as day 14, the mean total flux of all five Rag1-deficient
mice (4.0 × 106 +/− 7.9 × 106) was significantly greater
(p = 0.036, Wilcoxon Mann–Whitney rank sum test)
than that of the young wild type mice (9.5 × 104 +/−
1.7 × 104).
Selection of old C57BL/6 mice that resist 5T33 cell growth
Resistance of mice to progressive growth of 5T33 cells is
related to T cell function. Thus, Rag1-deficient mice that
lack T and B cells were the most susceptible to 5T33 cell
growth among mice that we have studied. Old mice, while
less susceptible than Rag1-deficient mice, are more sus-
ceptible to growth of 5T33 cells than young or B-cell defi-
cient mice (Figure 1). This suggests that immune
senescence compromises T-cell function required for pro-
tection from 5T33 cell growth. Although T cell function
declines with age, not all old animals are compromised to
the same extent. This likely explains why more than a
third of the old C57BL/6 old wildtype mice we studied
resisted the growth of 5T33 cells. This was consistent
with the hypothesis that about one third of old mice had
better preserved T-cell immunity that explained their re-
sistance to repeated challenge with 5T33 cells.
To investigate whether colonization of mice by 5T33
cells was a random event or reflected a characteristic of
individual mice, we repeatedly challenged a group of 34
18–20 month old C57BL/6 mice with 10 million 5T33
cells. Fifteen of these 34 mice allowed the growth of
5T33 cells as determined by the presence of the 5T33-
specific mIg in serum or, in its absence, the 5T33-
specific CDR3 mRNA peak. Twelve of the mice that did
not support the growth of 5T33 cells were rechallenged
with the same dose of 5T33 cells. Only one of these 12
old mice supported 5T33 cell growth. The remaining 11
mice were challenged for a third time with ten million
5T33 cells and none of these mice supported the 5T33
cell growth. These observations suggested that resistance
to 5T33 growth was a constitutional capacity of certain
old mice and not a random event, such as the injection
of different numbers of 5T33 MMM cells, extrinsic to
individual old mice.
Spleen cells from young, wild-type C57BL/6 mice inhibit
the growth of 5T33L MMM cells in Rag1-deficient C57BL/
6 mice
As discussed on page 5, 5T33 MMM cells grew in all
young, Rag1-deficient C57BL/6 mice. However, injection
of 5 to 20 million spleen cells from young, wild-type
C57BL/6 mice into young, Rag1-deficient C57BL/6 mice
1 week before the injection of 10 million 5T33 MMM
cells inhibited the growth of 5T33L MMM cells
(Figure 3). It should be noted, however, that in both
mice given only 5 million spleen cells from young, wild-
type C57BL/6 mice there was an early proliferation of
5T33L MMM cells before the growth of the 5T33L
MMM cells was suppressed (compare heavy dashed lines
with heavy solid lines in Figure 3). Similar results were
observed in a second experiment.
In contrast, complete protection from 5T33L MMM
cell growth was seen in all 4 young Rag1-deficient
C57BL/6 mice injected with 20 million spleen cells from
young wild-type C57BL/6 mice. Incomplete protection
was seen in young Rag-1 deficient mice with only 5 of
14 young Rag1-deficient C57BL/6 mice given 5 million
spleen cells from young, wild-type, C57BL/6 mice elim-
inating all 5T33L MMM cells. No protection from
5T33L MMM cell growth was seen in 3 young Rag1-
deficient C57BL/6 mice reconstituted with 1 million or
no spleen cells from young, wild type, C57BL/6 mice.
Young splenic T cells protected Rag1-deficient C57BL/6
mice from 5T33L MMM cell growth better than old
splenic T cells
The greater susceptibility of Rag1-deficient mice compared
to B-lymphocyte-deficient C57BL/6 mice to the growth of
5T33L MMM cells suggested that impaired T cell function
was the key to the greater susceptibility of Rag1-deficient
mice to 5T33L MMM cells. To prove this hypothesis,
purified splenic T cells (>95% CD3+) were prepared by
negative selection from the spleens of 3–4 month old,
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wild-type C57BL/6 mice using the “Easy-Sep” T cell en-
richment kit as described in the methods section. All 6
young Rag1-deficient C57BL/6 mice given 3 million puri-
fied splenic T cells from young wild-type C57BL/6 mice 1 -
week before the injection of 10 million 5T33L myeloma
cells were protected from the growth of 5T33L MMM
cells (Figure 4). In contrast, all 6 young Rag1-deficient
C57BL/6 mice given no purified splenic T cells from wild-
type C57BL/6 mice had progressive tumor cell growth.
Next, we determined the effect of age on the capacity
of splenic T cells to protect Rag 1-deficient C57BL/6
mice from a challenge with 10 million 5T33L MMM
cells. Three million, 1.5 million or 0.75 million splenic T
cells from 3–4 month or from 18–20 month old wild-
type C57BL/6 mice were injected into groups of 5 Rag-1
-deficient young mice before being challenged 1 week
later with 10 million 5T33L MMM cells. One group
included 12 Rag1-deficient young C57BL/6 mice which
received no T cells before being challenged with the in-
jection of 10 million 5T33L MMM cells. The second
group was divided into 3 groups of 5 young, Rag1-
deficient C57BL/6 mice given either 0.75, 1.5 or 3.0 mil-
lion splenic T cells from 18–20 month old C57BL/6
wild-type mice 1 week before the challenge with the an
injection of 10 million 5T33L MMM cells. The third
group was divided into 3 groups of 5 young, Rag1-
deficient C57BL/6 mice given either 0.75, 1.5 or 3.0
million splenic T cells from 3–4 month old C57BL/6
wild-type mice 1 week before the challenge with the an
injection of 10 million 5T33L MMM cells.
The results of this study are shown in Figure 5. In the
first group which included 12 young Rag1-deficient
C57BL/6 mice not given any splenic T cells prior to
challenge with 10 million 5T33L MMM cells, 11 of 12
(92%) mice showed progressive growth of 5T33L MMM
cells, indicated by increasing levels of photon flux, death,
or were sacrificed because of severe morbidity within 6 -
weeks. In group II, 8 of 15 mice (53%) which received
spleen T cells from 18–20 month old wild-type C57BL/6
Figure 3 Growth of 5T33L MMM cells were inhibited in two
groups of 2 C57BL/6 Rag1-deficient mice given either 5
million (−−–) or 20 milllion (−−−) HBSS-washed spleen cells
from 3 month-old C57BL/6 mice given 1 week before the
injection of 10 million 5T33L MMM cells compared to two
experiments in which a total of 6 C57BL/6 Rag1-deficient mice
received only HBSS (. . ..). Bioluminescent imaging of photon flux
(photons/sec) was measured 20 minutes of the injection of
luciferin and after 2, 11, 18, 28, 35, and 43 days after the injection
of 5T33L MMM cells. The difference between mice given and not
given spleen cells was statistically significant and this difference
increased progressively between 16 and 42 days after injection of
the 5T33L cells (Chi-square-Fisher exact test p < 0.005).
Figure 4 Inhibition of the growth of 10 million 5T33L MMM
cells injected into 6 C57BL/6 Rag1-deficient mice by 3 million
HBSS-washed splenic T cells from 3 month old C57BL/6 mice
1 week earlier (−−−) or in two experiments including a total of 6
C57BL/6 Rag1-deficient mice given no purified splenic T cells
from wild-type C57BL/6 mice had progressive tumor cell
growth (. . ..). One week later all C57BL/6 Rag1-deficient mice were
given 10 million 5T33L MMM cells. Photon flux was measured in all
12 mice 20 minutes after luciferin and 2, 11, 18, 28, 35, and 43 days
after the injection of 5T33L MMM cells. Photon flux from C57BL/6
Rag1-deficient mice given splenic T cells was significantly less than
photon flux from mice given only HBSS and this difference
increased progressively between 18 and 43 days after injection of
the 5T33L cells (Chi-square-Fisher exact test p < 0.0025).
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mice showed progressive growth of 5T33L MMM cells,
indicated by increasing levels of photon flux, death, or
were sacrificed because of severe morbidity within
6 weeks.
Statistical analysis of this experiment showed that the
administration of T cells from 18–20 month old mice
protected 3–4 month old mice significantly better from
tumor challenge than mice given no T cells (Chi-square
Fisher exact p = 0.043). However, most important, T cells
from 3–4 month old mice protected young Rag1-deficient
C57BL/6 mice significantly better than recipients of T cells
from 18–20 month old mice (Chi-square Fisher exact
p = 0.014).
Discussion
The increased susceptibility of old C57BL/6 wild-type
mice to 5T33 MMM cell growth is associated with the
decreased capacity of splenic T cells from old compared
to young, wild-type, C57BL/6 mice to protect C57BL/6
mice from the progressive growth of 5T33 MMM cells.
Future studies will be necessary to determine whether
young spleen T cells that appear to be more effective in
controlling the growth of 5T33L MMM cell-induced dis-
ease than old spleen T cells reflect the increased activity
of regulatory T cells in the spleen of old mice that impair
the capacity of young cytotoxic T cells to control the
growth of 5T33 MMM in C57BL/6 wild-type mice. An
age-associated increase in regulatory T cells that inhibit
cytotoxic activity of T cells from old mice and humans
has been reported [15,16].
Conclusions
We conclude that the increased proliferation of 5T33
MMM cells in old mice is due to the age-associated loss
of the T cell function that eliminates 5T33 MMM cells.
The mechanism of the immune senescent-associated
loss of murine T cell capacity to eliminate 5T33 MMM
cells remains to be established. Two alternatives come to
mind: (1) an age-associated loss of anti-tumor activity of
T cells, and/or (2) an age-associated suppression of T
cell anti-tumor activity by regulatory T cells. Whatever
the mechanism, successful reduction of 5T33 MMM-
induced mortality in old C57BL/6 mice would be
predicted to follow replacement of T cells in old mice
with T cells from young mice.
Material and methods
5T33 MMM cell growth
Cultured 5T33 MMM cells were obtained from Dr.
Babatunde Oyajobi (University of Texas. San Antonio,
TX 78229) and cultured in Iscove’s DMEM (Cellgro,
Herndon, VA) containing 25 mM L-glutamine, 25 mM
HEPES to which was added 10% fetal bovine serum
(FBS) and 1% Primocin (InvivoGen, San Diego, CA) in a
37°C, 5% CO2, humidified incubator. The cells were
maintained at a concentration below 500,000 cells/mL.
Prior to injection, these cells were washed in sterile
Hank’s Balanced Salt Solution (HBSS), counted, and re-
suspended in HBSS at a concentration of 50–100 million
cells/mL. A total of 10 million 5T33 MMM cells was
injected intravenously (IV) into mice in 0.1 to 0.2 ml of
HBSS.
Mouse husbandry and purchase
As male C57BL/6 mice fought when housed together, fe-
male mice, which could be housed 5 to a cage, were used
in this study and maintained in a barrier facility at the
Weill Cornell Medical College Research Animal Re-
source Facility. The growth of 5T33 MMM cells in four
groups of female mice was studied: young (3–4 month
old) or old (18–20 month old) wild-type C57BL/6 mice
obtained from the colony of aging mice maintained by
the National Institute on Aging at Harlan Laboratories
and two strains of young (3–4 month old) mutant C57BL/
young T cells
Figure 5 Groups of 5 young Rag1-deficient C57BL/6 mice were
given either 0.75, 1.5, or 3.0 million, wild-type splenic T cells
from 3–4 or 18–20 month old wild type C57BL/6 mice 7 days
prior to being challenged with 10 million 5T33L MMM cells. A
third group of 12 Rag1-deficient C57BL/6 mice were given no wild
type splenic T cells prior to being challenged with 10 million 5T33
MMM cells. Survival of C57BL/6 Rag1-deficient mice given splenic T
cells from 3–4 month old mice was significantly greater following
challenge with 10 million 5T33L MMM cells than that of C57BL/6
Rag1-deficient mice given T cells from 18–20 month old C57BL/6
1 week prior to challenge with 10 million 5T33L MMM cells (Chi
square statistic with Fisher exact test p < 0.017). A significantly
greater number (11 of 12) of young Rag1-deficient mice not given
any splenic T cells died following challenge with 5T33L MMM cells
than young Rag1-deficient mice given splenic T cells from old mice
prior to challenge with 5T33 MMM cells. (Chi-square-Fisher exact
test, p < 0.019). The inhibitory potency of young splenic T cells
compared to old splenic T cells was estimated to be 8 to1.
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6 mice B-cell-deficient C57BL/6.129S2-Igh-6tm1Cgn/J or
B- and T-cell deficient (Rag1-deficient) C57BL/6.127S7-
Rag11m1Mom/J obtained from the Jackson Laboratory (Bar
Harbor, ME). All animal-use protocols were approved by
the Weill-Cornell Medical College Institutional Animal
Care and Use Committee.
Experimental animal procedures
Mice were anesthetized by the intraperitoneal (IP) injec-
tion of 0.01 ml containing 10 mg of ketamineHCL and
1 mg xylazineHCL per ml water/gm body weight before
retro-orbital bleeding, sacrifice by cervical dislocation, or
partial splenectomy. Partial splenectomy was performed
by exposing the spleen through an abdominal incision
and ligation of the lower third of the spleen with surgical
thread. The peritoneal cavity was then closed with surgi-
cal sutures and the skin secured with surgical staples.
Preparation of spleen cells or splenic T cells for injection
Spleens from 3–4 or 18–20 month old wild-type C57BL/6
mice were removed under sterile conditions and single cell
suspensions prepared by passing the splenic tissue in RPMI
1640 (Cellgro, Herndon, VA) through a metal screen.
Erythrocytes in the spleen cell suspension were lysed by ex-
posure to distilled water for 15 seconds followed by the
addition of a 10% volume of 10X phosphate buffered saline
(PBS). Splenocytes were then collected by centrifugation
and washed in sterile HBSS. Splenic T cells were purified
by negative selection using a combination of biotinylated
monoclonal antibodies to cell surface antigens on mouse
hematopoietic cells linked to magnetic nanoparticles using
the “EasySep mouse” T cell enrichment kit according to
the manufacturer’s instructions (StemCell Technology,
Vancouver, CA). Total spleen cells and purified splenic T
cells were washed in HBSS, counted, and injected through
the tail vein into 3–4 month old Rag1-deficient C57BL/6
mice 1 week before they were challenged with 10 million
5T33L MMM cells injected into a tail vein.
Serum protein electrophoresis
Serum monoclonal immunoglobulins were detected by
serum protein electrophoresis (SPEP) gels prepared on
GelbondW films (Cambrex, Rockland, ME) using 1%
Seakem HE agarose in barbital buffer (Sigma-Aldrich, St.
Louis, MO) cast between 70°C glass plates and allowed
to cool to room temperature. The gels were then placed
at 4°C for one hour in a humidified chamber prior to
loading. Three μl of 2:1 serum sample:barbital buffer
were loaded per lane of a loading strip (SPIFE Urine/
CSF Protein Template, Helena Laboratories, Beaumont,
TX). The gels were run at 100 V for 25 minutes in a
Beckman-Coulter PEP apparatus (Fullerton, CA), fixed in
a 20% acetic acid and 30% methanol solution, and air
dried. The gels were then stained with a Paragon Blue
solution (Beckman-Coulter, Fullerton, CA) and de-stained
with sequential washes in 5% acetic acid, 20% acetic acid
and 30% methanol followed by drying at 70°C. SPEP band
density was quantified using ImageJ Version 1.37 (NIH,
Bethesda, MD). The background-subtracted density of
the mIg was divided by the density of the standard serum
mIg from a Rag1-deficient C57BL/6 mice injected seven
weeks earlier with 5T33 MMM cells.
Vector plasmid
A cytomegalovirus (CMV) promoter was constructed by
amplifying this promoter from the vector pcDNA3.1+/−
(Invitrogen, Camarillo, CA) by PCR using a forward
primer containing an XhoI site near the 50 end: 50-
TACTCGAGCAGATATACGCGTTGACATTC-30, and a
reverse primer with a HindIII site near its 50 end: 50-
ACAAGCTTTCTAGTTAGCCAGAGAGCTCTG-30. The
PCR product was digested with Xhol and HindIII, purified
using the Qiaquick PCR purification kit (Qiagen, Valencia,
CA), and inserted into the polylinker of the luciferase-
expression vector pGL4.20 (Promega, Madison, WI). The
final construct was confirmed by restriction enzyme and
partial sequence analysis.
Stable transfection of the luciferase gene
Ten million 5T33 MMM cells were suspended in 0.5 mL
of HBSS and transfected by electroporating 40 μg of PstI-
linearized construct of the luciferase gene using a Gene
Pulser Xcell Total System (Bio-Rad, Hercules, CA) set at
240 V and 500 μF capacitance. After incubation at 37°C
for 24 hours, puromycin (7 microgm/ml) was added to
the culture and the transfected (5T33L) MMM cells were
passed twice weekly at which time luciferase activity was
monitored in a Moonlight 2010 luminometer (Analytical
Luminescence Laboratory, San Diego, CA). After two
weeks of selection in puromycin medium, luciferase ex-
pression in the 5T33L cell line became stable and the cells
were thence forth grown in the absence of puromycin.
The 5T33L cells and the parent 5T33 cells showed no sig-
nificant differences in vitro or in vivo with respect to cell
growth, expression of CD138, or secretion of the 5T33-
specific IgG2b mIg. In addition, the IgH CDR3 cDNA
length and nucleotide sequences in 5T33 and 5T33L cells
were identical. In vivo, there was no difference in the
interval between the injection of 10 million 5T33 or
5T33L cells into Rag1-deficient mice and the appearance
of mIg in serum or of severe morbidity.
Bioluminescent imaging
The 5T33L cells were injected into shaved mice, anes-
thetized with isofluorine gas, injected IP with 300 μg
D-luciferin (Xenogen, Alameda, CA) in 200μL PBS, and
put in a light-tight chamber of an IVIS™ optical Imaging
System (Xenogen, Alameda, CA). Grayscale photographic
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images and pseudocolor bioluminescent images were
acquired. The total photon flux (photons/second) from
each mouse was determined using Xenogen Living Image™
software and graphed versus time using KaleidaGraph
(Synergy Software, Reading, PA). Background total flux
was measured in mice injected with luciferin but not with
5T33L cells.
Nucleic acid preparation
RNA or DNA was prepared from 5–10 million spleen or
bone marrow cells from mice as well as from cultured
or 5T33 MMM cells and extracted using RNeasyW or
DNeasyWKits (Qiagen, Valencia, CA) respectively. Up to 5
μg of extracted total RNA was reverse transcribed in 20 μL
reaction using Oligo(dT) primer and Superscript™ II re-
verse transcriptase (Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol.
IgH CDR3 mRNA and DNA length analysis
PCR products derived from the DNA and cDNA were
prepared as previously described [12]. PCR products
derived from DNA were made using a sense primer, spe-
cific for the J558 VH family (50-AAGGCCACACTG
ACTGTAGAC-30), and an anti-sense primer, specific for
the JH2 family (50-GACTGT GAGAGTGGTGCCTTG-
30). For the PCR products made from cDNA, the same
J558 VH forward primer was used with a C-region anti-
sense primer from exon I of the gamma chain C regions
(50-GGGAARTAVCCYTTGACMAGGCAYCC-30). Reac-
tion conditions were identical to those for the DNA re-
action. Presence of PCR products was confirmed by
electrophoresis on 1.5% agarose gels and visualization
with ethidium bromide.
CDR3 length analysis was done as previously described
(13). DNA or cDNA PCR products (2 ul) were used as
substrates for run-off PCR reactions with a 5T33-
specific fluorescent primer (50-FAM CAAAGCAGTTA
CCATAAGCCCTCTC -30). The elongation products
were diluted with equal volume of loading buffer (95%
formamide/10 mM EDTA), run on an acrylamide gel
using an automated ABI 373A DNA sequencer and
analyzed using Genescan 3.1 and Genotype 2.5 software
(Applied Biosystems, Foster City, CA).
Statistical analysis
Statistical analysis of differences among groups was
analyzed using the Kaplan-Meier statistic, the Wilcoxon-
Mann–Whitney rank sum test, or the Chi square statis-
tic evaluated by the Fisher exact test.
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